WO2000014217A3 - Oligonucleotides a motif g et leurs utilisations - Google Patents

Oligonucleotides a motif g et leurs utilisations Download PDF

Info

Publication number
WO2000014217A3
WO2000014217A3 PCT/EP1999/006502 EP9906502W WO0014217A3 WO 2000014217 A3 WO2000014217 A3 WO 2000014217A3 EP 9906502 W EP9906502 W EP 9906502W WO 0014217 A3 WO0014217 A3 WO 0014217A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleotide
present
composition
oligonucleotide
sequence
Prior art date
Application number
PCT/EP1999/006502
Other languages
English (en)
Other versions
WO2000014217A2 (fr
Inventor
Hermann Wagner
Grayson B Lipford
Klaus Heeg
Original Assignee
Cpg Immunopharmaceuticals Gmbh
Hermann Wagner
Grayson B Lipford
Klaus Heeg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cpg Immunopharmaceuticals Gmbh, Hermann Wagner, Grayson B Lipford, Klaus Heeg filed Critical Cpg Immunopharmaceuticals Gmbh
Priority to EP99946118A priority Critical patent/EP1108017A2/fr
Priority to CA002341338A priority patent/CA2341338A1/fr
Priority to AU58603/99A priority patent/AU777225B2/en
Publication of WO2000014217A2 publication Critical patent/WO2000014217A2/fr
Publication of WO2000014217A3 publication Critical patent/WO2000014217A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur une composition composée d'un oligonucléotide comprenant (a) la séquence N1-N2-G-N3-G, dans laquelle N1 représente tout nucléotide si N2 et N3 sont G; N2 représente tout nucléotide si N1 et N3 sont G; et N3 représente tout nucléotide si N1 et N2 sont G, ou (b) la séquence de (a), dans laquelle au moins un nucléotide est remplacé par un nucléotide correspondant analogue ou dérivé. L'invention porte en outre sur l'utilisation de la composition, et/ou du susdit pour la production d'une composition pharmaceutique destinée à prévenir ou traiter le choc septique, les inflammations, les maladies auto-immunes, les maladies induites par le TH1-, les infections bactériennes, les infections parasitaires, les infections virales, les avortements spontanés, et/ou les tumeurs.
PCT/EP1999/006502 1998-09-03 1999-09-03 Oligonucleotides a motif g et leurs utilisations WO2000014217A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP99946118A EP1108017A2 (fr) 1998-09-03 1999-09-03 Oligonucleotides a motif g et leurs utilisations
CA002341338A CA2341338A1 (fr) 1998-09-03 1999-09-03 Oligonucleotides a motif g et leurs utilisations
AU58603/99A AU777225B2 (en) 1998-09-03 1999-09-03 G-motif oligonucleotides and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98116652.3 1998-09-03
EP98116652 1998-09-03

Publications (2)

Publication Number Publication Date
WO2000014217A2 WO2000014217A2 (fr) 2000-03-16
WO2000014217A3 true WO2000014217A3 (fr) 2000-07-13

Family

ID=8232574

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/006502 WO2000014217A2 (fr) 1998-09-03 1999-09-03 Oligonucleotides a motif g et leurs utilisations

Country Status (4)

Country Link
EP (1) EP1108017A2 (fr)
AU (1) AU777225B2 (fr)
CA (1) CA2341338A1 (fr)
WO (1) WO2000014217A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723022B2 (en) 1994-07-15 2010-05-25 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7776344B2 (en) 1999-09-27 2010-08-17 University Of Iowa Research Foundation Methods related to immunostimulatory nucleic acid-induced interferon
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US8153141B2 (en) 2002-04-04 2012-04-10 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
US8834900B2 (en) 2001-08-17 2014-09-16 University Of Iowa Research Foundation Combination motif immune stimulatory oligonucleotides with improved activity
US9382545B2 (en) 2006-09-27 2016-07-05 Coley Pharmaceutical Gmbh CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0855184A1 (fr) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Composition pharmaceutique comprenant un polynucléotide et un antigène notamment pour la vaccination
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
NZ508927A (en) 1998-05-22 2003-12-19 Ottawa Health Research Inst Methods and products for inducing mucosal immunity
JP5084984B2 (ja) 1999-02-17 2012-11-28 シーエスエル、リミテッド 免疫原複合体およびそれに関する方法
CA2419894A1 (fr) 2000-09-15 2002-03-21 Coley Pharmaceutical Gmbh Procede de criblage a haut rendement d'immuno-agoniste/antagoniste base sur cpg
EP1450856B1 (fr) 2001-09-14 2009-11-11 Cytos Biotechnology AG Emballage de cpg dans des particules de type virus : procede de preparation et utilisation correspondante
EP1497424A1 (fr) 2002-04-22 2005-01-19 Bioniche Life Sciences Inc. Compositions d'oligonucleotides et leur utilisation pour la modulation de reponses immunitaires
CA2388049A1 (fr) 2002-05-30 2003-11-30 Immunotech S.A. Oligonucleotides immunostimulateurs et utilisations connexes
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
BR0315810A (pt) 2002-10-29 2005-09-13 Coley Pharmaceutical Group Ltd Uso de oligonucleotìdeos cpg no tratamento de infecção por vìrus da hepatite c
EP1578954A4 (fr) 2002-12-11 2010-08-11 Coley Pharm Group Inc Acides nucleiques 5'cpg et leurs methodes d'utilisation
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
WO2004084940A1 (fr) 2003-03-26 2004-10-07 Cytos Biotechnology Ag Encapsulation d'oligonucleotides immunostimulateurs dans des particules pseudovirales, procedes de preparation et utilisations
SG123799A1 (en) 2003-10-30 2006-07-26 Coley Pharm Gmbh C-class oligonucleotide analogs with enchanced immunostimulatory potency
KR100958505B1 (ko) 2004-07-18 2010-05-17 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
CA2630738C (fr) 2005-11-25 2013-09-03 Coley Pharmaceutical Gmbh Oligoribonucleotides immunostimulateurs
EP1973608A1 (fr) 2005-12-14 2008-10-01 Cytos Biotechnology AG Particules emballees avec des acides nucleiques immunostimulateurs pour le traitement de l hypersensibilite
SG172696A1 (en) 2006-06-12 2011-07-28 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
US7879812B2 (en) 2007-08-06 2011-02-01 University Of Iowa Research Foundation Immunomodulatory oligonucleotides and methods of use therefor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024380A1 (fr) * 1995-02-09 1996-08-15 Icn Pharmaceuticals, Inc. Methodes et compositions de regulation de l'expression de cd28
WO1998029430A1 (fr) * 1996-12-27 1998-07-09 Icn, Pharmaceuticals, Inc. Oligo-aptameres riches en proteine g et procede de modulation d'une reponse immunitaire
WO1998032462A1 (fr) * 1997-01-23 1998-07-30 Hermann Wagner Compositions pharmaceutique comportant un polynucleotide et eventuellement un antigene des plus utile en matiere de vaccination

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024380A1 (fr) * 1995-02-09 1996-08-15 Icn Pharmaceuticals, Inc. Methodes et compositions de regulation de l'expression de cd28
WO1998029430A1 (fr) * 1996-12-27 1998-07-09 Icn, Pharmaceuticals, Inc. Oligo-aptameres riches en proteine g et procede de modulation d'une reponse immunitaire
WO1998032462A1 (fr) * 1997-01-23 1998-07-30 Hermann Wagner Compositions pharmaceutique comportant un polynucleotide et eventuellement un antigene des plus utile en matiere de vaccination

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BALLAS, Z. ET AL.: "INDUCTION OF NK ACTIVITY IN MURINE AND HUMAN CELLS BY CPG MOTIFS IN OLIGODEOXYNUCLEOTIDES AND BACTERIAL DNA", JOURNAL OF IMMUNOLOGY, vol. 157, no. 5, September 1996 (1996-09-01), pages 1840-1845, XP002053416, ISSN: 0022-1767 *
KIMURA Y ET AL: "BINDING OF OLIGOGUANYLATE TO SCAVENGER RECEPTORS IS REQUIRED FOR OLIGONUCLEOTIDES TO AUGMENT NK CELL ACTIVITY AND INDUCE IFN", JOURNAL OF BIOCHEMISTRY, vol. 116, no. 5, November 1994 (1994-11-01), pages 991 - 994, XP000616565, ISSN: 0021-924X *
KRIEG A M ET AL: "THE ROLE OF CpG DINUCLEOTIDES IN DNA VACCINES", TRENDS IN MICROBIOLOGY, vol. 6, no. 1, January 1998 (1998-01-01), pages 23 - 26, XP000857633, ISSN: 0966-842X *
KRIEG, A.: "Leukocyte stimulation by oligodeoxynucleotides", STEIN, C.A. & KRIEG, A.M. 'APPLIED ANTISENSE OLIGONUCLEOTIDE TECHNOLOGY'. WILEY-LISS, NEW YORK, US;1998; CHAPTER 24, pages 431 - 448, XP002131392 *
LANG R. ET AL.: "Guanosine-rich oligodeoxynucleotides induce proliferation of macrophage progenitors in cultures of murine bone marrow cells.", EUR J IMMUNOL 1999 NOV;29(11):3496-506, XP000876859 *
PISETSKY DS. ET AL.: "The influence of base sequence on the immunostimulatory properties of DNA.", IMMUNOL RES 1999;19(1):35-46, XP000884065 *
SPARWASSER, T. ET AL.: "Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells.", EUR J IMMUNOL 1998 JUN;28(6):2045-54, XP002131393 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723022B2 (en) 1994-07-15 2010-05-25 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7879810B2 (en) 1994-07-15 2011-02-01 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7776344B2 (en) 1999-09-27 2010-08-17 University Of Iowa Research Foundation Methods related to immunostimulatory nucleic acid-induced interferon
US8834900B2 (en) 2001-08-17 2014-09-16 University Of Iowa Research Foundation Combination motif immune stimulatory oligonucleotides with improved activity
US8153141B2 (en) 2002-04-04 2012-04-10 Coley Pharmaceutical Gmbh Immunostimulatory G, U-containing oligoribonucleotides
US8658607B2 (en) 2002-04-04 2014-02-25 Zoetis Belgium Immunostimulatory G, U-containing oligoribonucleotides
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US9382545B2 (en) 2006-09-27 2016-07-05 Coley Pharmaceutical Gmbh CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity

Also Published As

Publication number Publication date
EP1108017A2 (fr) 2001-06-20
AU5860399A (en) 2000-03-27
AU777225B2 (en) 2004-10-07
CA2341338A1 (fr) 2000-03-16
WO2000014217A2 (fr) 2000-03-16

Similar Documents

Publication Publication Date Title
WO2000014217A3 (fr) Oligonucleotides a motif g et leurs utilisations
FI946201A0 (fi) Itsestabiloidut oligonukleotidit terapeuttisina aineina
AU6589094A (en) 7-deazapurine modified oligonucleotides
WO2000061151A3 (fr) Un oligodesoxynucleotide et son emploi pour induire une reponse immunitaire
EP1293503A4 (fr) Derives de triazole
WO2003008576A3 (fr) Oligonucleotides synthetiques a double brin utilises pour inhiber de façon ciblee l'expression genique
ATE465168T1 (de) Xylo-lna analoge
AU5121399A (en) Rna targeted 2'-modified oligonucleotides that are conformationally preorganized
EP2213736A3 (fr) Procédé d'inhibition de l'expression d'un gène cible et médicament destiné au traitement d'une maladie tumorale
WO2002085925A3 (fr) Ligands recepteurs de melanocortine
DE69934227D1 (de) Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide
ES2194779T3 (es) 1-aminotriazolo(4,3-a)quinazolin-5-onas y/o 5-tionas inhibidoras de fosfodiesterasa iv.
WO2001047944A3 (fr) Acides nucleiques contenant des polymorphismes mononucleotidiques et procedes d'utilisation correspondants
WO2001032832A3 (fr) Modulation antisens de l'expression de la nucleoline
ES2188760T3 (es) Oligonucleotidos especificos para el virus de la hepatitis b.
AU3295700A (en) Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same
EP0775745A3 (fr) Aptamères capables d'inhiber la cathépsine G
WO2000029623A3 (fr) Acides nucleiques contenant des polymorphismes d'un seul nucleotide et utilisations de ces acides nucleiques
WO2005046587A3 (fr) Preparation et composition de proteines d'inhibiteur inter-alpha a partir du plasma humain, a usage therapeutique
HUP9702251A2 (hu) Többfunkciós ligandumrendszer nukleinsavak sejtspecifikus bejuttatására
EP1448582A4 (fr) Interference avec l'activite de la telomerase
AU1070501A (en) Quantitation of rna transcripts using genomic dna as the internal amplification competitor
WO2003101405A3 (fr) Antibiotiques a base d'amino-glycosides et procedes d'utilisation correspondants
WO2005039480A8 (fr) Desoxyoligonucleotides antisens ache utilises comme agents anti-inflammatoires
WO2001040521A3 (fr) Acides nucleiques contenant des polymorphismes mononucleotidiques et procedes d'utilisation correspondants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2341338

Country of ref document: CA

Ref country code: CA

Ref document number: 2341338

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 58603/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999946118

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999946118

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09786436

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1999946118

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 58603/99

Country of ref document: AU